Extended Data Table 2 Pharmacokinetic parameters of divarasib in combination with cetuximab following multiple doses

From: Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

  1. Pharmacokinetic data from capsule and tablet formulations were pooled for this analysis. Analysis was performed with nominal time. Tmax is presented as median (range). All other statistics are presented as the mean ± s.d. Concentration values below the lower limit of quantification (BLLQ) before administration of the first dose were set to 0 and concentration values (BLLQ) after administration of the first dose administration were set to half the lower limit of quantification. Participants with dose reductions/interruptions were excluded from steady-state pharmacokinetic parameter analyses.
Back to article page